Cash position, page-5

From investor presentation March 2015 for capital raising.

Use of funds > These funds are budgeted to last until the end of Q3 2015 which will be following the expected release of pivotal clinical data relating to the INV103 (ala-Cpn10) and INV102 (nadolol) programs (anticipated within 3-4 months). It is expected that positive clinical data from one or both of these trials will position the company to negotiate a strategic investment in the company by a recognised biotech fund or provide a platform for a trade sale of the company or its assets.